Biogen (BIIB) said Tuesday that it has initiated dosing in the phase 3 Transcend study of felzartamab to treat adult kidney transplant recipients diagnosed with late antibody-mediated rejection, or late AMR.
The biotech company said the study, which will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo, will enroll approximately 120 kidney transplant recipients with late AMR.
The primary endpoint of study is the percentage of participants who achieve resolution by biopsy of AMR at 6 months.
Price: 149.33, Change: -1.38, Percent Change: -0.92
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。